In-vivo proof of concept in malignant melanoma
LU Bio has in total invested SEK 6,8 million in Cantargia and holds a position of 53%, others being the founders.
The company has previously presented significant anti malignant effects in an ex-vivo model of human leukemia. The project is based on the original discovery of IL1RAP as a unique receptor on leukemic stem cells in patients with chronic myeloid leukemia. The IL1RAP receptor has also been shown to be up-regulated on stem cells of AML and ALL.
"These results validate the concept in-vivo as well as represent an additional therapeutic target for an antibody based therapy against IL1RAP" says Agneta Svedberg, CEO of Cantargia.
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous